|

Antibody-Drug Conjugate Therapy Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • Mayo Clinic1

Indications

  • Stage IV Renal Pelvis and Ureter Cancer AJCC v71
  • Refractory Renal Pelvis and Ureter Urothelial Carcinoma1
  • Refractory Bladder Urothelial Carcinoma1
  • Metastatic Renal Pelvis and Ureter Urothelial Carcinoma1
  • Metastatic Bladder Urothelial Carcinoma1

Rochester, Minnesota1 trial

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

Mayo Clinic in Rochester

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.